Molecular Biosystems reported revenues of $3.1 million in its fiscal first quarter, up 82.3% compared with the $1.7 million posted in the same period in 1999.
For the period (end-June 30), the San Diego-based ultrasound contrast developer had a net loss of $282,000, compared with a net loss of $1.4 million in the first quarter of 1999. MBI reported growing sales of its Optison ultrasound contrast agent, with partner Mallinckrodt turning in a monthly record of slightly over $1 million in U.S. sales in June. Sales worldwide were just over $3 million in the first quarter, according to MBI.
By AuntMinnie.com staff writers
July 27, 2000
Related Reading
MBI cuts net loss in fiscal 2000, May 25, 2000.
Nycomed and Mallinckrodt settle patent suits, May 8, 2000.
MBI cuts staff by 58%, shifts focus to Optison, March 30, 2000.
MBI’s Optison agent begins radiology testing, March 28, 2000.
Merger between contrast firms MBI and Palatin collapses, March 14, 2000.
